Please visit ligand.com for more information.
Please visit ligand.com for more information.
XOMA Royalty plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s).
We have an expansive portfolio of licenses that provides us the right to future potential royalty and milestone payments. The drug candidate assets underlying the licenses are being developed by others.
We are actively acquiring the rights to future potential milestone and royalty payments to pre-commercial therapeutic assets being developed by pharmaceutical and biotech companies.
We use a portfolio approach to acquire new royalty assets, thereby mitigating single-asset binary exposure, and we operate under a capital-efficient structure to strive to deliver shareholder value.
[mc4wp_form id=”557″]
DOWNLOAD NOW »
April 16, 2021
Transaction Creates a Portfolio of More than 200 Biopharmaceutical Royalty Assets
July 14, 2026